{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:23:14Z","timestamp":1777623794717,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["#N01MH90001"],"award-info":[{"award-number":["#N01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.euroneuro.2014.08.004","type":"journal-article","created":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T12:16:01Z","timestamp":1408277761000},"page":"1615-1621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset"],"prefix":"10.1016","volume":"24","author":[{"given":"Eduardo","family":"Dunayevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao\u2010Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.euroneuro.2014.08.004_bib1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.08.004_bib999","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/sim.1647","article-title":"Points to consider on adjustment for baseline covariates","volume":"23","author":"Committee for proprietary medicinal products(CPMP)","year":"2004","journal-title":"Statist. Med"},{"key":"10.1016\/j.euroneuro.2014.08.004_bib3","unstructured":"European Medicines Agency (EMA), 2012. Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. Website: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/10\/WC500133437.pdf (accessed February 2014)."},{"issue":"5","key":"10.1016\/j.euroneuro.2014.08.004_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.jcp.0000236658.16286.25","article-title":"Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning","volume":"26","author":"Kinon","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2014.08.004_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.euroneuro.2014.08.004_bib6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/schbul\/sbi039","article-title":"Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim","volume":"32","author":"Laughren","year":"2006","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.euroneuro.2014.08.004_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/schbul\/sbq162","article-title":"Food and Drug Administration commentary on methodological issues in negative symptom trials","volume":"37","author":"Laughren","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.euroneuro.2014.08.004_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.euroneuro.2014.08.004_bib9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2014.08.004_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbq161","article-title":"Methodological issues in negative symptom trials","volume":"37","author":"Marder","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.euroneuro.2014.08.004_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-2004-832683","article-title":"Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial","volume":"37","author":"M\u00f6ller","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2014.08.004_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Oli\u00e9","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2014.08.004_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.schres.2013.06.023","article-title":"Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2014.08.004_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","article-title":"Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2014.08.004_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.schres.2011.09.028","article-title":"Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms","volume":"134","author":"Stauffer","year":"2012","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2014.08.004_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1400234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1400234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T13:50:17Z","timestamp":1538315417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1400234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0924977X1400234X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.08.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}